Milestone Scientific (MLSS) reported a third-quarter loss of $0.01 per share, unchanged from a year earlier, on revenue of $2.22 million, down 5.9% year over year. No consensus figures were available, so the most relevant benchmark is management's own forecast. On that basis the quarter fell short: revenue came in below the $2.3 million to $2.5 million range management gave on the second-quarter call. Management nonetheless sounded more confident. It pulled its profitability target forward to an expectation of approaching or achieving profitability in the fourth quarter of 2026, compared with earlier talk of cash-flow breakeven in early 2027. That is the central tension. The cost story improved while the revenue story slipped, yet the revised timeline depends on revenue doing something it has not yet done.

The flat per-share loss understates the operating progress. The net loss narrowed to $748,000 from $1.2 million a year ago and $1.1 million in the second quarter. Weighted shares rose to about 93.9 million from 82.0 million, which absorbed the improvement at the per-share level. Operating expenses fell 15.3% to $2.4 million, helped by lower compensation, stock-based compensation and professional fees. Gross margin expanded to 72.3% from 69.5% a year ago and 67.2% in the second quarter. However, the quality of that margin print deserves scrutiny. Management guided gross margin back to 69% to 70%, so investors should not extrapolate the third-quarter level. The revenue decline came from weaker dental product sales. Management framed this as seasonal moderation after a second quarter that benefited from two large international orders.

On the medical side, the headline reads better than the economics. Medical revenue rose 136% year over year, but that is a deceleration from 231% in the second quarter, and the base is tiny. Medical revenue was roughly $100,000 in the quarter, about in line with the first quarter's $108,000, and was mostly new capital sales. Management said recurring disposable revenue, the core of the CompuFlo thesis, is not expected to become meaningful until around mid-first to second quarter of 2027, given a four- to six-month lag. The commercial build-out is real, however:

• Five dedicated medical reps, about 15 consultants and three distributors are now working more than 500 U.S. leads.
• Federal market access runs through Red One Medical.
• Rothman Orthopaedics has begun clinical use of CompuFlo.
• The 22-location Pain and Spine Specialists network joined the CompuFlo Advisor Program.

Completed online demonstrations more than doubled year over year in the first nine months, which supports the improving-demand narrative even though it has not yet shown up in reported sales.

The forward setup hinges on the fourth quarter. Management reaffirmed full-year revenue guidance of $9.8 million to $10.2 million. With nine-month revenue at about $7.2 million, that implies a fourth quarter of roughly $2.6 million to $3.0 million, a steep step-up from $2.2 million. It also lands right on the $2.6 million to $2.7 million quarterly threshold management cited as near breakeven. In other words, the profitability call and the revenue guide are effectively the same bet. Some timelines are already slipping. Mexico and India registrations moved to the first quarter of 2027 after being expected sooner, Japan is on hold, and management acknowledged a learning curve and field-training constraints on utilization. The catalyst list has offsetting items:

• An approved Turkey dental registration with a first order indicated.
• Talks with four dental distribution channels.
• International licensing discussions with larger medtech firms.
• A provisional patent for intrathecal pump refills.

All of these are early-stage rather than revenue-producing.

The balance sheet is cleaner but thin. Converting director loans to equity left Milestone debt-free. Cash, however, fell to $1.3 million from $2.1 million at the end of the second quarter, and no new raise was disclosed. Accounts payable climbed to $2.25 million from $1.43 million at year-end, while inventory dropped by about $1.0 million, suggesting working capital has been helping to fund operations. The roughly $400,000 in additional annual savings helps, but at this scale every quarter of missed revenue matters.

Market data offers limited context this time. Shares opened at $0.48 after the August report, and the 200-day moving average sits near $0.35. Current price and sentiment readings were not available, so there is no clean read on how investors priced the miss against the improved profitability timeline.

The bottom line is that Milestone delivered genuine cost discipline, margin improvement and a broadening medical sales infrastructure, but missed its own revenue range and now needs a sharp fourth-quarter acceleration to validate both its full-year guidance and its newly accelerated profitability target. Bears have legitimate ammunition in the revenue shortfall, slowing medical growth, slipping international registrations and a $1.3 million cash balance. Bulls can point to a narrower loss and a more scalable go-to-market effort. The fourth quarter will show which side was right.